Rigel Pharmaceuticals | RIGL - Operating Profit


Rigel Pharmaceuticals reported $14.06M in Operating Profit for its fiscal quarter ending in September of 2024.





Operating Profit Change Date
Agenus USD 15.05M 656K Mar/2026
Amgen USD 4.61B 777M Jun/2026
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD -170.09M 28.83M Jun/2026
AstraZeneca USD 3.16B 3.95B Jun/2026
BioMarin Pharmaceutical USD 105.6M 24.04M Jun/2026
Bristol-Myers Squibb USD 299M 3.07B Jun/2026
Celldex Therapeutics USD -80.62M 3.81M Jun/2026
Daiichi Sankyo JPY 85.1B 4.44B Jun/2026
Eli Lilly USD 12.46B 2.68B Jun/2026
Halozyme Therapeutics USD -63.72M 1.95M Jun/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Intrexon USD -60.84M 26.62M Jun/2024
Ionis Pharmaceuticals USD -102.29M 15.71M Jun/2026
Karyopharm Therapeutics USD -26.76M 8.92M Mar/2026
Ligand Pharmaceuticals USD 56.62M 3.7M Jun/2026
MacroGenics USD -33.44M 21.34M Mar/2026
Neurocrine Biosciences USD 219.9M 5.3M Jun/2026
Pfizer USD 667M 4.32B Jun/2026
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Rigel Pharmaceuticals USD 14.06M 13.61M Sep/2024
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Ultragenyx Pharmaceutical USD -75M 141M Jun/2026
Veracyte USD 23.96M 4.88M Jun/2026